BNP Paribas Financial Markets’s Theriva Biologics TOVX Stock Holding History

BNP Paribas Financial Markets’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Hold	0	–	–	–	5022
2022 Q2	–	Hold	0	–	–	–	4247
2022 Q1	–	Hold	0	–	–	–	4364
2021 Q4	–	Hold	0	–	–	–	4266
2021 Q3	–	Hold	0	–	–	–	4082
2021 Q2	–	Hold	0	–	–	–	4047
2021 Q1	–	Hold	0	–	–	–	3988
2020 Q4	–	Hold	0	–	–	–	4221
2020 Q3	–	Hold	0	–	–	–	4282
2020 Q2	–	Hold	0	–	–	–	4300
2020 Q1	–	Hold	0	–	–	–	4453
2019 Q4	–	Hold	0	–	–	–	4494
2019 Q3	–	Hold	0	–	–	–	4549
2019 Q2	–	Hold	0	–	–	–	4533
2019 Q1	–	Hold	0	–	–	–	4276
2018 Q4	–	Hold	0	–	–	–	4321
2018 Q3	–	Hold	0	–	–	–	4430
2018 Q2	–	Hold	0	–	–	–	4402
2018 Q1	–	Hold	0	–	–	–	4203
2017 Q4	–	Hold	0	–	–	–	4196
2017 Q3	–	Hold	0	–	–	–	4192
2017 Q2	–	Sell	-1	Closed	-$4.98K	–	4228
2017 Q1	$3.1K	Hold	1	–	–	﹤0.01%	3417
2016 Q4	$8.25K	Hold	1	–	–	﹤0.01%	3536
2016 Q3	$8.85K	Buy	+1	New	+$15K	﹤0.01%	3230
2016 Q2	–	Hold	0	–	–	–	3240
2014 Q3	–	Hold	0	–	-$1.9K	–	4276
2014 Q2	–	Hold	0	–	–	–	3140
2014 Q1	–	Hold	0	–	–	–	2730
2013 Q4	–	Hold	0	–	–	–	3731

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BNP Paribas Financial Markets's TOVX Position: Q3 2022 in Review

BNP Paribas Financial Markets held its Theriva Biologics (TOVX) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5022.

BNP Paribas Financial Markets first reported a position in TOVX in Q3 2016 and has held it in 3 quarters since. The position peaked at $8.85K in Q3 2016. 24 funds tracked by Wall St. Rank hold TOVX as of Q3 2022.

BNP Paribas Financial Markets held 0 shares of Theriva Biologics worth $0 as of Q3 2022.
BNP Paribas Financial Markets left its Theriva Biologics share count unchanged in Q3 2022.
Theriva Biologics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q3 2022, its #5022 holding.
BNP Paribas Financial Markets first reported a position in Theriva Biologics in Q3 2016 and has held it in 3 quarters since.
BNP Paribas Financial Markets's Theriva Biologics position peaked at $8.85K in Q3 2016.
24 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2022, filed 15 Nov 2022.